Spero Therapeutics (SPRO) Operating Expenses (2016 - 2026)

Spero Therapeutics has reported Operating Expenses for 11 years, with the latest figure at $7.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 62.16% year-over-year to $7.8 million; the trailing twelve-month figure through Mar 2026 stood at $47.7 million (down 59.83% YoY), and the FY2025 full-year result was $60.5 million, down 50.15% from the prior year.
• Operating Expenses for Q1 2026 stood at $7.8 million, down from $9.9 million in the prior quarter.
• The five-year high for Operating Expenses was $36.8 million in Q4 2024, with the low at $7.8 million in Q1 2026.
• Historically, Operating Expenses has averaged $21.6 million across 5 years, with a median of $21.5 million in 2022.
• Annual changes were most pronounced in 2023 — Operating Expenses surged 98.03% — and 2025, when it sank 73.1%.
• Spero Therapeutics' Operating Expenses stood at $21.5 million in 2022, then gained by 6.85% to $23.0 million in 2023, then soared by 59.93% to $36.8 million in 2024, then slumped by 73.1% to $9.9 million in 2025, then fell by 21.19% to $7.8 million in 2026.
• The last three Operating Expenses figures came in at $7.8 million (Q1 2026), $9.9 million (Q4 2025), and $13.4 million (Q3 2025), per Business Quant data.